Antibe Therapeutics sees article highlighting its anti-inflammatory drug published in medical journal

Antibe Therapeutics Inc (CVE:ATE) (OTCMKTS:ATBPF) announced Monday that an article showcasing the benefits of its anti-inflammatory drug candidate has been published in a medical journal.

The piece, which appeared in the publication "Antioxidant and Redox Signaling," reported on a series of studies of ATB-352, the company’s derivative of the nonsteroidal anti-inflammatory drug (NSAID) ketoprofen.

The studies show that ATB-352 induces greater pain relief than ketoprofen in a well-characterized animal model of surgical pain.

READ: Antibe Therapeutics bolsters executive team in preparation for ATB-346 commercialization

In addition to blocking the production of pain-promoting substances called "prostaglandins", the company said, ATB-352 further reduced pain by elevating levels of naturally-occurring endocannabinoids in comparison to the levels of endocannabinoids observed in mice treated with ketoprofen.

Like ketoprofen, ATB-352 treats pain by releasing hydrogen sulfide, but Antibe's alternative is being developed to also avoid some of its side effects, namely damage to the gastrointestinal tract.

The studies were led by Antibe Chief Science Officer John Wallace and featured researchers from the University of Calgary in Canada; the University of Sao Paulo and the University of Campinas in Brazil; and Umea University in Sweden.

The journal article is titled, "Enhanced Analgesic Effects and GI Safety of A Novel Hydrogen Sulfide-Releasing Anti-Inflammatory Drug (ATB?352): A Role for Endogenous Cannabinoids."

Toronto-based Antibe is also working to develop and commercialize its lead drug, ATB-346, which targets acute and chronic pain associated with osteoarthritis.

Contact Andrew Kessel at andrew.kessel@proactiveinvestors.com

Follow him on Twitter @andrew_kessel

Proactive Investors facilitate the largest global investor network across 4 continents in 4 languages. With a team of analysts, journalists & professional investors Proactive produce independent coverage on 1000's of companies across every sector for private investors, private client brokers, fund managers and international investor communities.
No investment advice

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. You understand that the Content on the Site is provided for information purposes only, and none of the information contained on the Site constitutes an offer, solicitation or recommendation to buy or sell a security. You understand that the Company receives either monetary or securities compensation for our services. We stand to benefit from any volume which any Content on the Site may generate.

You further understand that none of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value, suitability or profitability of any particular security, portfolio of securities, transaction, investment, investment strategy, or other matter.

You understand that the Site may contain opinions from time to time with regard to securities mentioned in other products, including Company-related products, and that those opinions may be different from those obtained by using another product related to the Company. You understand and agree that contributors may write about securities in which they or their firms have a position, and that they may trade such securities for their own account. In cases where the position is held at the time of publication and such position is known to the Company, appropriate disclosure is made. However, you understand and agree that at the time of any transaction that you make, one or more contributors may have a position in the securities written about. You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate.

From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

The Site does not, and is not intended to, provide investment, tax, accounting, legal or insurance advice, and is not and should not be construed as providing any of the foregoing. You should consult an attorney or other relevant professional regarding your specific legal, tax, investment or other needs as tailored to your specific situation.

In exchange for publishing services rendered by the Company on behalf of Antibe Therapeutics, Inc. named herein, including the promotion by the Company of Antibe Therapeutics, Inc. in any Content on the Site, the Company receives from said issuer annual aggregate cash compensation in the amount up to Twenty Five Thousand dollars ($25,000).